Mirvat Alasnag, MD, spoke to Cardiovascular Business about CCTA's growing influence in cardiology. 

AccurECG 2.0 was designed to interpret a total of 13 different rhythm classifications, including atrial fibrillation, atrial flutter and ventricular tachycardia. 

A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.

Florida-based Cardiovascular Associates of America, one of the largest private equity-backed cardiology management groups in the United States, just got a little bigger.

A veteran cardiologist is back on the job after reportedly being fired for his participation in a controversial CDC panel. His wife shared the update, saying they were "truly humbled" by everyone who came to his defense.

Based on feedback from the FDA, Aspire Biopharma plans on completing a multicenter clinical trial and then seeking regulatory approval for its new high-dose sublingual aspirin therapy. 

ASE President David Wiener, MD, discussed his goals for 2026 in a new video interview. "The imager who doesn't use artificial intelligence will be replaced by the imager who does,” he said.

Early evidence suggests CBD could help clinicians treat pericarditis, myocarditis and other significant heart conditions. Additional research is still required, however, including many more clinical trials.

This update helps health systems get more value out of UltraSight's advanced AI technology—all without buying brand new ultrasound equipment.

Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care?

Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.

The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure.

Keto-diet champions will like the new food pyramid’s emphasis on proteins, including those high in saturated fats. Not everyone shares their predisposition. 

During a recent segment on Fox Business, Food and Drug Administration Commissioner Martin Makary, MD, clarified new guidance on AI, meant to provide companies with the flexibility to gather and provide data without the agency's approval. However, medical devices that provide "clinical-grade" data will still need to be cleared.